Compare Your Knowledge of AQXP To The Crowd's

has been on quite the rollercoaster since the beginning of last week. The stock shot up from under $1 after the close on Thursday to more than $40 by mid-day on Monday. The rapid gains came in response to promising secondary endpoint results in a phase 2 trial for a drug aimed at treating interstitial cystitis, a painful bladder condition. But since they peaked on Monday, shares have plummeted and now settled at just around $20. So clearly, investors were swept up in a wave of optimism after the initial news, probably supporting an unwarrantedly high valuation for the Canadian firm. Did traders buy AQXP without appropriate fundamental knowledge of the company and its new drug? It's very likely. Answer the questions below to test your perceptions of Aquinox against the rest of the crowd. In an effort to remain as fair as possible, the correct answers won't be revealed until later this week.